Esperion Therapeutics, Daiichi Sankyo Europe Ink $125 Mln Amendment To Their Collaboration

RTTNews | 610 일 전
Esperion Therapeutics, Daiichi Sankyo Europe Ink $125 Mln Amendment To Their Collaboration

(RTTNews) - Esperion Therapeutics, Inc. (ESPR) and Daiichi Sankyo Europe GmbH or DSE, the European arm of Japanese pharmaceutical company Daiichi Sankyo Co., Ltd. (DSKYF.PK), announced Wednesday a $125 million amendment to their collaboration, which includes an amicable resolution to their commercial dispute and certain other adjustments to enhance the long-term value of their products.

DSE has agreed to pay Esperion $100 million in mid-January ahead of an anticipated Type II(a) variation approval by the European Medicines Agency (EMA) for NILEMDO (bempedoic acid) Tablet and NUSTENDI (bempedoic acid and ezetimibe) Tablet.

DSE will make an additional $25 million payment to Esperion in the calendar quarter immediately following EMA's decision on the pending application.

The legal action pending in the United States District Court for the Southern District of New York will be dismissed.

Since 2019, Esperion and DSE have worked together to bring bempedoic acid to the eligible patient population and unlock its potential for cardiovascular risk reduction. The partnership continues to grow, with DSE recently gaining approvals for bempedoic acid in the Netherlands, Slovakia, and Spain.

read more
Merck, Daiichi Sankyo Say FDA Grants Priority Review In U.S. For Patritumab Deruxtecan

Merck, Daiichi Sankyo Say FDA Grants Priority Review In U.S. For Patritumab Deruxtecan

Merck & Co. Inc. (MRK) and Japan's Daiichi Sankyo Co. Ltd. (DSKYF.PK) announced Friday that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the Biologics License Application (BLA) for patritumab deruxtecan (HER3-DXd) for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies.
RTTNews | 622 일 전
U.S. Weekly Jobless Claims Rise More Than Expected

U.S. Weekly Jobless Claims Rise More Than Expected

A day ahead of the release of the more closely watched monthly jobs report, the Labor Department released a report on Thursday showing first-time claims for U.S. unemployment benefits rose by more than expected in the week ended August 30th.
RTTNews | 28 분 전
Bay Street May Open With Negative Bias On Weak Commodity Prices

Bay Street May Open With Negative Bias On Weak Commodity Prices

The Canadian market is likely to open with a negative bias on Friday, tracking weak crude oil and bullion prices. The focus is on the ADP data from the U.S., due this morning, and the Canadian and U.S. jobs reports, due on Friday, for clues about the rate decisions by the central banks of the two nations.
RTTNews | 40 분 전
FTSE Modestly Higher; Airline Stocks Drift Lower

FTSE Modestly Higher; Airline Stocks Drift Lower

The U.K. stock market is modestly higher in early afternoon trades on Thursday as investors making purchases at select counters amid expectations the Federal Reserve will announce an interest rate cut in its upcoming monetary policy meeting.
RTTNews | 1 시간 6 분 전
CAC 40 Down Slightly; Sanofi Tanks Nearly 10%

CAC 40 Down Slightly; Sanofi Tanks Nearly 10%

French stocks are turning in a mixed performance on Thursday with investors largely making cautious moves while looking ahead to crucial economic data, including U.S. private sector jobs data, due later in the day, and U.S. non-farm payroll employment report, due on Friday.
RTTNews | 1 시간 27 분 전